30 November 2015 - The extent of the additional clinical benefit varies by the type of prior therapy, however: It is non-quantifiable when biologics have been used, and minor without prior therapy with biologics.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/secukinumab-in-psoriasis-now-indication-of-added-benefit-for-certain-patients.7068.html